Funds holding Inhibrx Biosciences Inc
ISIN US45720N1037 · United States
- Fund holders
- 132
- Of which ETFs
- 28 104 other funds
- Value held
- 183.9M $
- Share of capital
- 16.3 % of 14.7M shares on Aug 7, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| SA Franklin Allocation Moderately Aggressive Portfolio SEASONS SERIES TRUST | 476 | 32K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Longboard Fund NORTHERN LIGHTS FUND TRUST II | 435 | 32.2K $ | 0.03 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Small-Cap Equity Portfolio PACIFIC SELECT FUND | 411 | 27.6K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| iShares Morningstar Small-Cap ETF iShares Trust | 396 | 51.2K $ | 0.02 % | 0.00 % | as of Apr 30, 2026 ↗ |
| ProShares Russell 2000 High Income ETF ProShares Trust | 391 | 29K $ | 0.02 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Morgan Stanley Pathway Small-Mid Cap Equity ETF MORGAN STANLEY PATHWAY FUNDS | 377 | 27.9K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Victory Cornerstone Aggressive Fund Victory Portfolios III | 357 | 26.5K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Putnam VT Global Asset Allocation Fund Putnam Variable Trust | 309 | 20.8K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| EQ/Franklin Small Cap Value Managed Volatility Portfolio EQ Advisors Trust | 300 | 20.2K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SmallCap Value Fund II Principal Funds, Inc | 292 | 37.7K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 238 | 16K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Destinations Small-Mid Cap Equity Fund Brinker Capital Destinations Trust | 220 | 16.3K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Nationwide Fundamental All Cap Equity Portfolio Nationwide Mutual Funds | 213 | 27.5K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| State Street Total Return V.I.S. Fund STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 208 | 14K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| TIAA Separate Account VA-1 - Stock Index Account TIAA Separate Account VA-1 | 203 | 13.6K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Penn Series Small Cap Index Fund Penn Series Funds Inc | 200 | 13.4K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Nuveen Life Stock Index Fund TIAA-CREF Life Funds | 119 | 8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ULTRA SMALL CAP PROFUND ProFunds | 102 | 13.2K $ | 0.02 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 64 | 8.3K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Small Company Value Portfolio Wilshire Mutual Funds Inc | 60 | 4K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 46 | 3.1K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Wilshire 5000 Index Fund Wilshire Mutual Funds Inc | 38 | 2.6K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 30 | 2K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 23 | 1.5K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 21 | 1.4K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 17 | 2.2K $ | 0.03 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 12 | 806.8 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 10 | 672.3 $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 9 | 667.2 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 3 | 222.4 $ | 0.02 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 2 | 134.5 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| BlackRock Advantage Small Cap Growth Fund BlackRock Funds | 1 | 67.2 $ | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 1.20 % | as of Apr 30, 2026 ↗ |
| First Trust Small Cap Growth AlphaDEX Fund First Trust Exchange-Traded AlphaDEX Fund | 0.86 % | as of Apr 30, 2026 ↗ |
| Invesco Dorsey Wright SmallCap Momentum ETF Invesco Exchange-Traded Fund Trust II | 0.78 % | as of Feb 28, 2026 ↗ |
| First Trust Small Cap Core AlphaDEX Fund First Trust Exchange-Traded AlphaDEX Fund | 0.44 % | as of Apr 30, 2026 ↗ |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 0.42 % | as of Apr 30, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 0.37 % | as of Apr 30, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 0.36 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.27 % | as of Mar 31, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 0.26 % | as of Mar 31, 2026 ↗ |
| Invesco Russell 2000 Dynamic Multifactor ETF Invesco Exchange-Traded Self-Indexed Fund Trust | 0.23 % | as of Feb 28, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 132 | +15 | 2,394,761 | +18.3 % |
| 2026Q1 | 117 | +16 | 2,023,785 | +42.4 % |
| 2025Q4 | 101 | +9 | 1,421,508 | -6.8 % |
| 2025Q3 | 92 | -9 | 1,525,679 | -7.4 % |
| 2025Q2 | 101 | -3 | 1,648,180 | -4.2 % |
| 2025Q1 | 104 | +5 | 1,720,824 | +15.8 % |
| 2024Q4 | 99 | +2 | 1,485,742 | +22.6 % |
| 2024Q3 | 97 | 1,212,046 |
Institutional managers
127 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 1,442,707 | 97M $ | as of Mar 31, 2026 |
| VIKING GLOBAL INVESTORS LP | 1,437,705 | 96.7M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 1,263,078 | 84.9M $ | as of Mar 31, 2026 |
| Sanofi | 1,157,926 | 77.8M $ | as of Mar 31, 2026 |
| HighTower Advisors, LLC | 870,200 | 58.5M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 798,898 | 53.7M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 550,845 | 37M $ | as of Mar 31, 2026 |
| Sofinnova Investments, Inc. | 406,029 | 27.3M $ | as of Mar 31, 2026 |
| Capital Research Global Investors | 392,847 | 26.4M $ | as of Mar 31, 2026 |
| Woodline Partners LP | 384,433 | 25.8M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 327,860 | 22M $ | as of Mar 31, 2026 |
| PFM Health Sciences, LP | 305,431 | 20.5M $ | as of Mar 31, 2026 |
| Schonfeld Strategic Advisors LLC | 254,827 | 17.1M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 231,509 | 15.6M $ | as of Mar 31, 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 170,700 | 11.5M $ | as of Mar 31, 2026 |
| SummitTX Capital, L.P. | 137,821 | 9.3M $ | as of Mar 31, 2026 |
| Soleus Capital Management, L.P. | 131,000 | 8.8M $ | as of Mar 31, 2026 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | 125,000 | 8.4M $ | as of Mar 31, 2026 |
| CDC Financial, Inc. | 124,530 | 8.4M $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 97,873 | 6.6M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 95,074 | 6.4M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 93,696 | 6.3M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 77,437 | 5.2M $ | as of Mar 31, 2026 |
| KENNEDY CAPITAL MANAGEMENT LLC | 72,812 | 4.9M $ | as of Mar 31, 2026 |
| CITIGROUP INC | 62,516 | 4.2M $ | as of Mar 31, 2026 |
Declared shareholders of Inhibrx Biosciences Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Perceptive Advisors LLC and 2 others | 9.99 % | 1,461,105 | as of Mar 31, 2026 · SCHEDULE 13G |
| VIKING GLOBAL INVESTORS LP and 10 others | 9.99 % | 1,461,633 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Inhibrx Biosciences Inc". https://titelia.com/en/stocks/inhibrx-biosciences-inc-US45720N1037